Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia

14Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

This retrospective study aimed to evaluate the relationship between plasma autoantibody species and rhTPO response in adult ITP patients who failed the first-line treatments. Plasma anti-glycoprotein (GP) IIb/IIIa and anti-GPIb/IX autoantibodies were detected in 47·2% and 40·6% of the 123 patients, respectively. Overall response rate to rhTPO treatment in patients without anti-GPIb/IX autoantibodies was significantly higher than patients with anti-GPIb/IX autoantibodies (82·2% vs. 60·0%, P = 0·006). By contrast, no statistical difference in response rate was observed between patients with or without anti-GPIIb/IIIa autoantibodies (74·1% vs. 72·3%, P = 0·819). Therefore, the presence of anti-GPIb/IX autoantibodies might serve as a predictive factor for poor response to rhTPO treatment in ITP.

Cite

CITATION STYLE

APA

Yu, Y., Hou, Y., Zhao, Y., Zhou, H., Jing, F., Liu, Y., … Hou, M. (2021). Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. British Journal of Haematology, 194(1), 191–194. https://doi.org/10.1111/bjh.17510

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free